Bellevue Group AG
- SEC CIK
- 0001674546
- Latest filing
- Aug 14, 2026
INBX holding history
Inhibrx Biosciences, Inc. in every 13F filed by Bellevue Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
INBX overviewAll 13F holders of INBXFull Q2 2026 holdings
- Shares (Q1 2024)
- 0
- Sold out in Q1 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2024 | 0 | $0 | 0.0% | −24,600−100.0% | Sold out | Holders |
| Q4 2023 | 24,600 | $934.8K | <0.1% | −24,200−49.6% | Reduced | Holders |
| Q3 2023 | 48,800 | $895.5K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 48,800 | $1.27M | <0.1% | +19,100+64.3% | Added | Holders |
| Q1 2023 | 29,700 | $560.4K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 29,700 | $731.8K | <0.1% | −13,800−31.7% | Reduced | Holders |
| Q3 2022 | 43,500 | $781.0K | <0.1% | −33,100−43.2% | Reduced | Holders |
| Q2 2022 | 76,600 | $869.0K | <0.1% | +26,900+54.1% | Added | Holders |
| Q1 2022 | 49,700 | $1.11M | <0.1% | −800−1.6% | Reduced | Holders |
| Q4 2021 | 50,500 | $2.21M | <0.1% | +50,500 | New | Holders |